1. Show article details.

    AlloVir's Posoleucel Shows Early Safety In Kidney Transplant Recipients

    Benzinga – 12:07 PM ET 06/07/2022

    AlloVir's Posoleucel Shows Early Safety In Kidney Transplant Recipients

  2. Show article details.

    BRIEF-Allovir Reports Blinded Preliminary Phase 2 Data Supporting The Ongoing Study Of Posoleucel

    Reuters – 8:32 AM ET 06/07/2022

    Allovir Inc (ALVR): * ALLOVIR REPORTS BLINDED, PRELIMINARY, PHASE 2 DATA SUPPORTING THE ONGOING STUDY OF POSOLEUCEL, A MULTI-VIRUS-SPECIFIC T CELL THERAPY, FOR THE TREATMENT OF BK VIREMIA IN KIDNEY TRANSPLANT RECIPIENTS. * Allovir Inc (ALVR) - PHASE 2 STUDY COMPLETED ENROLLMENT AHEAD OF SCHEDULE. * Allovir Inc (ALVR) - POSOLEUCEL WELL-TOLERATED WITH NO CASES OF GRAFT REJECTION OBSERVED TO DATE.

  3. Show article details.

    AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

    Business Wire – 8:30 AM ET 06/07/2022

    Phase 2 study completed enrollment ahead of schedule Posoleucel well-tolerated with no cases of graft rejection observed to date Overall decline in median BK viral load among patients completing 12 weeks of dosing with posoleucel or placebo Posoleucel detected up to 12 weeks after last infusion Topline, unblinded study results from all 61 patients expected to be released in 1Q 2023 WALTHAM, Mass.

  4. Show article details.

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    Benzinga – 5:46 PM ET 06/01/2022

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

  5. Show article details.

    90 Biggest Movers From Yesterday

    Benzinga – 5:44 AM ET 05/13/2022

    90 Biggest Movers From Yesterday

  6. Show article details.

    58 Stocks Moving In Thursday's Mid-Day Session

    Benzinga – 12:03 PM ET 05/12/2022

    58 Stocks Moving In Thursday's Mid-Day Session

  7. Show article details.

    Stocks That Hit 52-Week Lows On Wednesday

    Benzinga – 12:28 PM ET 05/11/2022

      On Wednesday, 807 companies reached new 52-week lows. The following stocks created new 52-week lows on Wednesday: Be sure to stay with Benzinga for further updates and market-moving news.

  8. Show article details.

    Recap: AlloVir Q1 Earnings

    Benzinga – 8:58 AM ET 05/05/2022

      AlloVir reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. AlloVir beat estimated earnings by 13.75%, reporting an EPS of $-0.69 versus an estimate of $-0.8. Revenue was down $0.00 from the same period last year.

  9. Show article details.

    BRIEF-Allovir Reports First Quarter 2022 Financial Results

    Reuters – 7:17 AM ET 05/05/2022

    Allovir Inc (ALVR): * ALLOVIR REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS. * Q1 LOSS PER SHARE $0.69 Source text for Eikon: Further company coverage:

  10. Show article details.

    AlloVir Reports First Quarter 2022 Financial Results

    Business Wire – 7:00 AM ET 05/05/2022

    Initiated posoleucel registrational study to prevent six devastating viral infections and now enrolling high-risk allo-HCT patients in the U.S., Western Europe and Asia FDA granted RMAT designation to posoleucel for Phase 3 multi-virus prevention indication with an estimated annual addressable patient population of 40,000 allo-HCT patients Progressed enrollment in three Phase 3 studies for poso...

  11. Show article details.

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    Benzinga – 8:16 AM ET 04/28/2022

      This article was generated by Benzinga's automated content engine and reviewed by an editor.

  12. Show article details.

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    Benzinga – 5:39 PM ET 04/27/2022

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

  13. Show article details.

    Stocks That Hit 52-Week Lows On Monday

    Benzinga – 12:01 PM ET 04/25/2022

      On Monday, 721 companies achieved new lows for the year. During Monday, the following stocks set new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.

  14. Show article details.

    56 Biggest Movers From Friday

    Benzinga – 4:23 AM ET 04/25/2022

  15. Show article details.

    Stocks That Hit 52-Week Lows On Friday

    Benzinga – 12:26 PM ET 04/22/2022

      On Friday, 431 companies hit new 52-week lows. Here are all the stocks that set new 52-week lows on Friday: Be sure to stay with Benzinga for further updates and market-moving news.

  16. Show article details.

    53 Biggest Movers From Yesterday

    Benzinga – 4:52 AM ET 04/21/2022

  17. Show article details.

    Mid-Afternoon Market Update: Dow Jumps Around 300 Points; AlloVir Shares Spike Higher

    Benzinga – 2:31 PM ET 04/20/2022

    U.S. stocks traded mixed toward the end of trading, with the Dow Jones climbing around 300 points on Wednesday. The Dow traded up 0.85% to 35,206.75 while the NASDAQ fell 0.96% to 13,488.42. The S&P also rose, gaining, 0.16% to 4,469.17. Also check this: 4 Stocks Under $5 Insiders Are Aggressively Buying Leading and Lagging Sectors Real estate shares jumped by 1.9% on Wednesday.

  18. Show article details.

    Mid-Day Market Update: Nasdaq Down Over 150 Points; Netflix Shares Drop Following Earnings Report

    Benzinga – 12:19 PM ET 04/20/2022

    U.S. stocks traded mixed midway through trading, with the Nasdaq composite dropping more than 150 points on Wednesday. The Dow traded up 0.76% to 35,176.54 while the NASDAQ fell 1.17% to 13,460.26. The S&P also rose, gaining, 0.03% to 4,463.70. Also check this: 4 Stocks Under $5 Insiders Are Aggressively Buying Leading and Lagging Sectors Real estate shares jumped by 1.5% on Wednesday.

  19. Show article details.

    28 Stocks Moving In Wednesday's Mid-Day Session

    Benzinga – 12:13 PM ET 04/20/2022

    28 Stocks Moving In Wednesday's Mid-Day Session

  20. Show article details.

    Mid-Morning Market Update: Markets Mixed; Dow Jumps 250 Points

    Benzinga – 10:45 AM ET 04/20/2022

    U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 250 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.76% to 35,176.49 while the NASDAQ fell 0.60% to 13,537.29. The S&P also rose, gaining, 0.21% to 4,471.63.

Page:

Today's and Upcoming Events

  • Aug
    04

    ALVR to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    05

    ALVR announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.